SAGE Therapeutics (NASDAQ: SAGE) announced that SAGE-547 demonstrated robust activity, with a 77 percent response rate in evaluable patients with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Sage Therapeutics (SAGE) PT Raised to $70 at Leerink Partners as New Data Corroborates Prior Promising ResultsMay 14, 2015 11:03 AM SAGE Therapeutics (SAGE) Misses Q1 EPS by 17cMay 14, 2015 6:33 AM SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status EpilepticusMay 14, 2015 6:15 AM SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status EpilepticusMay 14, 2015 6:15 AM